Oticon Medical’s Sentio™ System Receives Regulatory Clearance in the US
Oticon Medical announced today the U.S. Food and Drug Administration (FDA) clearance of its first active transcutaneous bone conduction hearing system, the Sentio System. Sentio System delivers the proven benefits of the Ponto™ System – and more – in a transcutaneous option.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240712765107/en/
The Sentio System includes an external Sentio 1 Mini sound processor and a Sentio Ti Implant placed under the skin. (Photo: Business Wire)
The system includes Sentio 1 Mini, an external sound processor, and Sentio Ti Implant, placed under the skin. It is the smallest transcutaneous system available to date1.
While Ponto and other percutaneous bone-anchored hearing systems use skin-protruding abutments, the Sentio System provides an alternative keeping the skin intact. The Sentio System offers an additional solution for patients and supports our commitment to "freedom of choice."
“With the launch of Sentio System, we provide best-in-class and the smallest active transcutaneous system. More importantly, Oticon Medical now offers a complete portfolio of bone-anchored hearing systems. This portfolio meets the needs of patients and customers, and fits diverse clinical settings and global reimbursement schemes for the treatment. We strongly believe that offering a broad portfolio is the path to achieving our mission to "Help more people" and give more potential users the quality of life improvements these systems offer”, says René Govaerts, President & General Manager, Oticon Medical.
The Sentio 1 Mini is designed with a focus on user comfort and ease of use. The device's design and slim profile make it 26% lighter than an alternative1. It gives access to a 360-degree sound experience and offers the widest bandwidth of 9.5kHz.
Sentio Ti is a SuperPowerful implant developed to support patient’s progressive hearing loss, without the need for additional surgeries. Sentio Ti is designed and verified for a higher maximum force output, so that patients can rely on its ability to handle more powerful sound processors2. From a surgeon’s perspective, the implant is designed for surgical flexibility, ensuring a straightforward procedure.
Sentio System is indicated for candidates aged 12 and older who have been diagnosed with conductive hearing loss, mixed hearing loss, or single-sided deafness.
This launch marks a significant milestone for Oticon Medical, as it continues to deliver the innovative hearing solutions that help people live life to the fullest.
For more information visit www.oticonmedical.com.
Not all products are available in all markets. Product availability and indications are subject to regulatory approval and may vary depending on the market.
About Oticon Medical
Oticon Medical is a global company in implantable hearing solutions, dedicated to bringing the power of sound to people at every stage of life. For more than a decade, we have made bone anchored hearing systems more accessible by simplifying the treatment for physicians, audiologists, and patients alike.
We believe that patients and hearing care professionals should be able to choose the best possible solution at any time along the patient journey. We call it “Freedom of Choice” and it has always been paramount to Oticon Medical. This is the reason why our solutions are designed to be compatible whenever possible. As a result, an implant from Oticon Medical stands as a true testament to our unwavering lifelong support.
We work collaboratively with professionals to ensure that every solution we create is designed with our users’ needs in mind. We have a strong passion to provide innovative solutions and support that enhance quality of life and help people live life to the fullest – now and in the future.
Because we know how much sound matters.
References
1 Sentio implant and sound processor physical features and comparison to other devices (Doc-00123204)
2 275144en Product Information Sentio 1 Mini
View source version on businesswire.com: https://www.businesswire.com/news/home/20240712765107/en/
Contacts
Erik Lund
Marketing Director, Oticon Medical
E-mail: erld@oticonmedical.com
Mobile: +46 76 304 4482
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citigroup Announces Approximately €452 Million Redemption Of 4.25% Fixed Rate/Floating Rate Subordinated Notes Due 203024.1.2025 14:30:00 CET | Press Release
Citigroup Inc. is announcing the redemption, in whole, constituting €451,934,000 of its 4.25% Fixed Rate / Floating Rate Subordinated Notes due 2030 (the “notes”) (ISIN: XS0213026197). The redemption date for the notes is February 25, 2025 (the “redemption date”). The cash redemption price for the notes payable on the redemption date will equal par plus accrued and unpaid interest, to but excluding, the redemption date. The redemption announced today is consistent with Citigroup's liability management strategy and reflects its ongoing efforts to enhance the efficiency of its funding and capital structure. Citigroup will continue to consider opportunities to redeem or repurchase securities, based on several factors, including without limitation, the economic value, regulatory changes, potential impact on Citigroup's net interest margin and borrowing costs, the overall remaining tenor of Citigroup's debt portfolio, capital impact, as well as overall market conditions. Beginning on the re
AI’s Impact on Elections: New Policy Paper Highlights Urgent Global Challenge24.1.2025 13:01:00 CET | Press Release
Artificial intelligence (AI) is transforming political campaigns worldwide, creating unprecedented opportunities while amplifying risks for democratic processes. According to the newly launched policy paper, The Pervasive Influence of AI on Global Political Campaigns 2024, AI-driven techniques, such as generative AI (genAI), have revolutionized voter engagement through personalized messaging. However, genAI has also emerged as a double-edged sword: while enabling effective campaigning, it has been a significant source of disinformation, eroding trust in democratic institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122148789/en/ Future Shift Labs Co-founder Sagar Vishnoi addresses IPE25 in Cape Town (Photo: Business Wire) For instance, the United States, classified as “severely polarized” and ranked 3rd among 28 countries for polarization, illustrates how AI-generated propaganda exacerbates societal divisions. Fu
ContourGlobal Scales up U.S. Renewables Presence With Acquisition of 446 MWp Solar PV Portfolio From Qcells24.1.2025 11:29:00 CET | Press Release
ContourGlobal and Qcells have announced a strategic transaction for a U.S. solar PV portfolio located in Colorado and Virginia with an installed capacity of 446 MWp. This transaction expands ContourGlobal’s planned solar PV and BESS capacity in the United States to almost 1.5 GW, when combined with more than 1 GW of recently acquired projects in late development stage located in South Carolina and Arizona. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122055737/en/ Antonio Cammisecra, CEO ContourGlobal (Photo: Business Wire) Mr. Antonio Cammisecra, CEO of ContourGlobal, commented, “This transaction allows us to maintain momentum in our U.S. renewable growth, nearing 1.2 GW of solar PV capacity complemented with additional 0.3 GW of BESS capacity, in construction or late development. It also meaningfully accelerates the start of our commercial operations to the first half of this year. We are proud of this milestone and d
WEF25: Saudi Arabia “Rewriting the Economic Playbook”24.1.2025 11:00:00 CET | Press Release
Saudi Arabia’s delegation to the World Economic Forum (WEF) Annual Meeting today shared its strategy for rewriting the economic playbook during several key sessions, including one led by the Kingdom on its economic transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250124094652/en/ His Excellency Faisal F. Alibrahim, Minister of Economy and Planning (Photo: AETOSWire) In the session titled ‘Saudi Arabia’s Economic Shifts’, His Excellency Mohammed A. Aljadaan, Minister of Finance, described the main forces driving the Kingdom’s transformation: “The whole nation has been mobilized behind Saudi Vision 2030. There’s a very clear vision that the people, the business community, and the government are all driving towards. We have a leadership that takes a long-term view, prepared to make tough decisions, and to be consistent.” Earlier, in ‘The Road Ahead for Scaling AI’, His Excellency Abdullah A. Alswaha, Minister of C
Caranx Medical Announces FDA Submission of TAVIPILOT Soft: the World’s first AI Software for Real-time Intra-operative Guidance of Transcatheter Heart Valve Implantation24.1.2025 09:00:00 CET | Press Release
Caranx Medical (“Caranx”), a French medical device company specializing in the development of an autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced FDA submission of the world first AI Software for real-time intra-operative guidance of transcatheter heart valve implantation. The FDA submission marks a significant milestone of Caranx strategy towards planned market introduction of TAVIPILOT Soft by end of 2025. “The team at Caranx has achieved an important milestone in the submission to the Food and Drug Administration, FDA. This extremely promising step paves the way to early commercialization of the TAVIPILOT Soft by end 2025. I am very excited about the real-time guidance of TAVI/TAVR, a key to accurate and precise positioning of the heart valve as well as the promotion of potentially more predictable and controlled valve deployment” says CEO of Caranx Jorgen Hansen “Allowing a broader number of cardiologi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom